報價延遲最少15分鐘:2026/09/23 21:43 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
19.97 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.85/--
|
|
企業價值
1.38B
|
| 資產負債 |
|
每股賬面淨值
-4.16
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches. |
